
Cassel Salpeter & Co.’s Q3 healthcare update points to disrupted NIH grant processing, FDA attrition, and tariffs as pressures on drug development and early-stage financing.
Clearstate Pte. Ltd.
and
United BioSource Corporation (UBC)
announced a strategic partnership to provide global market access, pricing, and reimbursement strategies for manufacturers of biopharmaceuticals, medical devices, and other medical technology.
The agreement reinforces Clearstate’s position as a source for accurate and actionable market intelligence across the Asia-Pacific region and builds upon UBC’s leadership in delivering global market access strategies for life science products. The alliance provides UBC and its clients with access to the high quality market access, pricing, and reimbursement information.






